PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN CORONA VIRUS DISEASE (COVID-19)
A pharmaceutical composition for treating acute respiratory distress syndrome (ARDS), multiple end organ failure and survival in serious and life-threatening condition in patients with coronavirus disease 2019 (COVID-19) including (a) centhaquine; (b) antiviral therapies for SARS-CoV-2 infection (remdesivir, ivermectin, chloroquine, hydroxychloroquine, azythromicyn, tenofovir, emtricitabine, ritonavir, lopinavir, ASC09, favipiravir, danoprevir, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), recombinant human angotensin-converting enzyme 2 (rhACE2), xiyanping, alpha-interferon, fludase (DAS 181), eicosapentaenoic acid free fatty acid (EPA-FFA), nitric oxide, PUL-042, Pam2CSK4 acetate, agonists of TLR2 TLR6, and TLR9), convalescent plasma, stem cells or their exosomes, immunomodulation and cytokine-targeted therapies (itolizumab, tocilizumab, sarilumab, acalabrutinib, piclidenoson, tradipitant, CD24Fc, emapalumab, anakinra, TJ003234, BLD-2660, blood purification systems, Spectra Optia Apheresis System, corticosteroids) oxygen concentrator and generator, T89, dantonic, plasminogen supplementation, plasminogen activators, alteplase; (c) budesonide, supportive therapies to reduce fever (like acetaminophen or ibuprofen), steroids (dexamethasone, prednisolone), anticoagulants (aspirin, heparin, non-heparin anticoagulants such as argatroban, bivalirudin, danaparoid, fondaparinux or a direct oral anti-coagulant (DOAC), (d) inhaled synthetic surfactant, antibody to endotoxin, interferon-beta- 1 a, IV prostaglandin EL neutrophil elastase inhibitors, nitric oxide and (e) an excipient. A method for preparing the composition for treating acute respiratory distress syndrome, multiple end organ failure and shock symptoms caused by coronaviruses infection, in particular SARS-CoV-2, MERS-CoV and SARS-CoV, using centhaquine and its analogues compound by mechanism of reduction of edema in the lungs, improvement in ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (Pa02ZFi02 or Sp02ZFi02), blood oxygen saturation(Sp02), normalization in respiratory rate, reduction in lung infiltration, improvement in ARDS score, MODS, Ordinal Scale of COVID-19, and better blood flow and oxygenation of tissues..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 16. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
GULATI ANIL [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-11-16, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 |
|---|
| Patentnummer: |
AU2022273692 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018634656 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018634656 | ||
| 003 | DE-627 | ||
| 005 | 20240209082729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231201s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018634656 | ||
| 035 | |a (EPA)AU2022273692 | ||
| 035 | |a (EPA)83999346 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a GULATI ANIL |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN CORONA VIRUS DISEASE (COVID-19) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-11-16, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 | ||
| 520 | |a A pharmaceutical composition for treating acute respiratory distress syndrome (ARDS), multiple end organ failure and survival in serious and life-threatening condition in patients with coronavirus disease 2019 (COVID-19) including (a) centhaquine; (b) antiviral therapies for SARS-CoV-2 infection (remdesivir, ivermectin, chloroquine, hydroxychloroquine, azythromicyn, tenofovir, emtricitabine, ritonavir, lopinavir, ASC09, favipiravir, danoprevir, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), recombinant human angotensin-converting enzyme 2 (rhACE2), xiyanping, alpha-interferon, fludase (DAS 181), eicosapentaenoic acid free fatty acid (EPA-FFA), nitric oxide, PUL-042, Pam2CSK4 acetate, agonists of TLR2 TLR6, and TLR9), convalescent plasma, stem cells or their exosomes, immunomodulation and cytokine-targeted therapies (itolizumab, tocilizumab, sarilumab, acalabrutinib, piclidenoson, tradipitant, CD24Fc, emapalumab, anakinra, TJ003234, BLD-2660, blood purification systems, Spectra Optia Apheresis System, corticosteroids) oxygen concentrator and generator, T89, dantonic, plasminogen supplementation, plasminogen activators, alteplase; (c) budesonide, supportive therapies to reduce fever (like acetaminophen or ibuprofen), steroids (dexamethasone, prednisolone), anticoagulants (aspirin, heparin, non-heparin anticoagulants such as argatroban, bivalirudin, danaparoid, fondaparinux or a direct oral anti-coagulant (DOAC), (d) inhaled synthetic surfactant, antibody to endotoxin, interferon-beta- 1 a, IV prostaglandin EL neutrophil elastase inhibitors, nitric oxide and (e) an excipient. A method for preparing the composition for treating acute respiratory distress syndrome, multiple end organ failure and shock symptoms caused by coronaviruses infection, in particular SARS-CoV-2, MERS-CoV and SARS-CoV, using centhaquine and its analogues compound by mechanism of reduction of edema in the lungs, improvement in ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (Pa02ZFi02 or Sp02ZFi02), blood oxygen saturation(Sp02), normalization in respiratory rate, reduction in lung infiltration, improvement in ARDS score, MODS, Ordinal Scale of COVID-19, and better blood flow and oxygenation of tissues. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 16. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:16 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/83999346/publication/AU2022273692A1?q=AU2022273692 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 16 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 16 |c 11 | ||